Cytek BioSciences Inc
CTKB
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
95.7% downsideOvervalued by 95.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $596.64 Million |
|---|---|
| Enterprise Value | $574.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.52 |
| Beta | 1.17 |
| Outstanding Shares | 128,704,934 |
Return
| Return on Equity | -22.59% |
|---|---|
| Return on Assets | -16.48% |
| Return on Invested Capital | -11.29% |
Valuation & Multiples
| P/E Ratio | -8.01 |
|---|---|
| PEG | -12.23 |
| Price to Sales | 4.62 |
| Price to Book Ratio | 2.31 |
| Enterprise Value to Revenue | 2.82 |
| Enterprise Value to EBIT | -13.82 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 66.58% |
|---|---|
| Total Invested | $64,084▼ 99.98% |
| Investors Holding | 3▼ 162.00% |
ESG Score
No data
About Cytek BioSciences Inc
2,021 employeesRelevant Senate Committees
The committee controls trade policy/tariffs (impacting Cytek's international supply chain) and R&D tax credits, which are essential for the valuation of high-growth tech firms.
The Labor-HHS-Education subcommittee determines the specific annual budget for the NIH and CDC, which directly influences the purchasing power of Cytek's core customer base.
This committee regulates the FDA and NIH. The NIH is the primary funder for Cytek's academic customers, and the FDA regulates the clinical use of their diagnostic tools.